Impact of systemic therapy on circulating leukocyte populations in patients with metastatic breast cancer

被引：19

作者：

Larsson, Anna-Maria ^{[1
,2
]}

Roxa, Anna ^{[1
]}

Leandersson, Karin ^{[3
]}

Bergenfelz, Caroline ^{[3
,4
]}

机构：

[1] Lund Univ, Dept Clin Sci Lund, Div Oncol & Pathol, Lund, Sweden

[2] Skane Univ Hosp, Dept Hematol Oncol & Radiat Phys, Lund, Sweden

[3] Lund Univ, Dept Translat Med, Canc Immunol, S-21428 Malmo, Sweden

[4] Lund Univ, Dept Translat Med, Expt Infect Med, S-21428 Malmo, Sweden

来源：

SCIENTIFIC REPORTS | 2019年 / 9卷 / 1期

关键词：

SUPPRESSOR-CELLS; PERIPHERAL-BLOOD; T-CELLS; CHEMOTHERAPY; PHENOTYPE; TAMOXIFEN;

D O I：

10.1038/s41598-019-49943-y

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Tumors affect the immune system, locally and systemically. The frequencies of specific circulating immune cell populations correlate with disease progression as well as prognosis of the patients. Although largely neglected, conventional antitumoral therapies often possess immunomodulatory properties and affect the levels of specific immune cell populations. Most information, however, derive from animal or in vitro studies. As this could impact prognosis as well as response to therapy, further studies of the effects of treatment on circulating immune cells in patients are warranted. In this pilot study, we evaluated a wide panel of circulating immune cells over time (up to six months) in ten patients with metastatic breast cancer receiving standard antitumoral regimens. Overall, endocrine therapy tends to enrich for natural killer (NK) and natural killer T (NKT) cells in the circulation, whereas both chemotherapy and endocrine therapy reduce the levels of circulating monocytic myeloid-derived suppressor cells (Mo-MDSCs). This indicates that the systemic immunosuppressive profile observed in patients tends to revert over the course of systemic therapy and holds promise for future combination treatment with standard antitumoral agents and immunotherapy.

引用

页数：10

共 37 条

[11] Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy [J].

Diaz-Montero, C. Marcela ;

Salem, Mohamed Labib ;

Nishimura, Michael I. ;

Garrett-Mayer, Elizabeth ;

Cole, David J. ;

Montero, Alberto J. .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2009, 58 (01) :49-59

[12] Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials [J].

Dowsett, M. ;

Forbes, J. F. ;

Bradley, R. ;

Ingle, J. ;

Aihara, T. ;

Bliss, J. ;

Boccardo, F. ;

Coates, A. ;

Coombes, R. C. ;

Cuzick, J. ;

Dubsky, P. ;

Gnant, M. ;

Kaufmann, M. ;

Kilburn, L. ;

Perrone, F. ;

Rea, D. ;

Thuerlimann, B. ;

van de Velde, C. ;

Pan, H. ;

Peto, R. ;

Davies, C. ;

Gray, R. ;

Baum, M. ;

Buzdar, A. ;

Sestak, I. ;

Markopoulos, C. ;

Fesl, C. ;

Jakesz, R. ;

Colleoni, M. ;

Gelber, R. ;

Regan, M. ;

von Minckwitz, G. ;

Snowdon, C. ;

Goss, P. ;

Pritchard, K. ;

Anderson, S. ;

Costantino, J. ;

Mamounas, E. ;

Ohashi, Y. ;

Watanabe, T. ;

Bastiaannet, E. .

LANCET, 2015, 386 (10001) :1341-1352

[13] Palbociclib and Letrozole in Advanced Breast Cancer [J].

Finn, Richard S. ;

Martin, Miguel ;

Rugo, Hope S. ;

Jones, Stephen ;

Im, Seock-Ah ;

Gelmon, Karen ;

Harbeck, Nadia ;

Lipatov, Oleg N. ;

Walshe, Janice M. ;

Moulder, Stacy ;

Gauthier, Eric ;

Lu, Dongrui R. ;

Randolph, Sophia ;

Dieras, Veronique ;

Slamon, Dennis J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (20) :1925-1936

[14]

Fitzmaurice C, 2017, JAMA ONCOL, V3, P524, DOI [10.1001/jamaoncol.2016.5688, 10.1001/jamaoncol.2018.2706]

[15] Specific MDR1 P-glycoprotein blockade inhibits human alloimmune T cell activation in vitro [J].

Frank, MH ;

Denton, MD ;

Alexander, SI ;

Khoury, SJ ;

Sayegh, MH ;

Briscoe, D .

JOURNAL OF IMMUNOLOGY, 2001, 166 (04) :2451-2459

[16] Peripheral blood immunologic phenotype of population-based breast cancer cases and matched controls [J].

Goedert, James J. ;

Pfeiffer, Ruth ;

Zhu, Mingzhu ;

Yang, Xiaohong R. ;

Garcia-Closas, Montserrat ;

Lissowska, Jolanta ;

Kopp, William C. .

EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2012, 42 (05) :572-574

[17] Etiology and Outcome of Extreme Leukocytosis in 758 Nonhematologic Cancer Patients A Retrospective, Single-Institution Study [J].

Granger, John M. ;

Kontoyiannis, Dimitrios P. .

CANCER, 2009, 115 (17) :3919-3923

[18] Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment [J].

Hanahan, Douglas ;

Coussens, Lisa M. .

CANCER CELL, 2012, 21 (03) :309-322

[19] Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer [J].

Hortobagyi, G. N. ;

Stemmer, S. M. ;

Burris, H. A. ;

Yap, Y. -S. ;

Sonke, G. S. ;

Paluch-Shimon, S. ;

Campone, M. ;

Blackwell, K. L. ;

Andre, F. ;

Winer, E. P. ;

Janni, W. ;

Verma, S. ;

Conte, P. ;

Arteaga, C. L. ;

Cameron, D. A. ;

Petrakova, K. ;

Hart, L. L. ;

Villanueva, C. ;

Chan, A. ;

Jakobsen, E. ;

Nusch, A. ;

Burdaeva, O. ;

Grischke, E. -M. ;

Alba, E. ;

Wist, E. ;

Marschner, N. ;

Favret, A. M. ;

Yardley, D. ;

Bachelot, T. ;

Tseng, L. -M. ;

Blau, S. ;

Xuan, F. ;

Souami, F. ;

Miller, M. ;

Germa, C. ;

Hirawat, S. ;

O'Shaughnessy, J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (18) :1738-1748

[20]

Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.21492, 10.3322/caac.20115, 10.3322/caac.20107]

← 1 2 3 4 →